MedOne offers expedited access to Stelara biosimilars
The much-anticipated biosimilars for ustekinumab, commonly known by its brand name Stelara, are set to hit the market in mid-2025.
The much-anticipated biosimilars for ustekinumab, commonly known by its brand name Stelara, are set to hit the market in mid-2025.
“Terry has been a visionary and disciplined leader in making NACDS meetings and conferences the gold standard in the industry,” said NACDS president and CEO Steven Anderson.
NovoCare Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients.
Matrix Global Advisors report highlights current barriers and recommendations for robust competition and patient savings in the next decade.
CoverMyMeds' 2025 Medication Access Report: From Barriers to Bridges calls for increased collaboration and interoperability across the healthcare industry to improve patient outcomes.
As lawmakers prioritize health, CRN’s 2025 Day on the Hill will highlight the industry’s crucial role in offering safe, effective, science-backed nutrition products.
With latest transaction, Wellvana supports primary care providers across 40 states, serving approximately 1 million patients.
In 2025, the number of people without commercial insurance coverage for these medications surged significantly. Zepbound saw a 14% increase since 2024, leaving 4.9 million people without coverage, and Ozempic saw a 22% increase, affecting another 1.1 million people.
One webinar will explore practical strategies for managing stress, mastering self-care, and fostering a resilient, well-supported working environment.
"We are encouraged by statements from President Trump and Speaker Johnson that the most damaging proposals regarding Medicaid have been taken off the table."
Transforming the patient health care experience.
Winning companies are selected by the distributor and manufacturer member executives of the HDA Industry Relations Council.
“Matt's leadership, dedication to innovation and commitment to excellence have made him a standout in the healthcare distribution industry."
Beyond prescription delivery, the partnership will also enhance access to wellness products.
Since its launch in 2023, ShiftRx has successfully connected thousands of pharmacists and pharmacy technicians to both full-time and flexible work opportunities.
This brings the company's total U.S. capital expansion commitments to more than $50 billion since 2020.